As of close of business last night, Moderna Inc’s stock clocked out at $103.79, down -0.07% from its previous closing price of $103.86. On the day, 2164122 shares were traded.
Ratios:
To gain a deeper understanding of MRNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.42. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, HSBC Securities on February 26, 2024, Downgraded its rating to Reduce and sets its target price to $86 from $75 previously.
On January 02, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $142.
On November 29, 2023, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $82.Canaccord Genuity initiated its Hold rating on November 29, 2023, with a $82 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 15 ’24 when Hoge Stephen sold 15,000 shares for $105.02 per share. The transaction valued at 1,575,300 led to the insider holds 1,486,241 shares of the business.
AFEYAN NOUBAR sold 15,000 shares of MRNA for $1,606,865 on Apr 10 ’24. The Director now owns 2,071,931 shares after completing the transaction at $107.12 per share. On Apr 08 ’24, another insider, Mock James M, who serves as the Chief Financial Officer of the company, sold 705 shares for $101.93 each. As a result, the insider received 71,859 and left with 5,048 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 5.80 while its Price-to-Book (P/B) ratio in mrq is 2.86.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $156.75, while it has fallen to a 52-week low of $62.55.
Shares Statistics:
A total of 382.00M shares are outstanding, with a floating share count of 336.34M. Insiders hold about 12.15% of the company’s shares, while institutions hold 67.54% stake in the company.
Earnings Estimates
As of right now, Moderna, Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $1.20, with high estimates of $16.20 and low estimates of $23.91.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
